The UP-Hemophilia Conclave 2026, organized by the Uttar Pradesh Hematology Group (UPHG) in association with King George's Medical University (KGMU), convened distinguished hematologists, clinical specialists, diagnostic experts, and HTC Nodal Officers representing 19 district Hemophilia Treatment Centers (HTCs) from across Uttar Pradesh.

Dr SP Verma was organising Secretary and Dr Rashmi Kushwaha was co-organising Secretary for this programme.

The conclave served as a multi-stakeholder expert panel to synthesize operational realities, establish consensus on Standard Treatment Guidelines (STGs), and formulate key policy recommendations to be submitted for administrative review and implementation by the leadership of National Health Mission (NHM) and Directorate of Medical Education (DGME), Uttar Pradesh. The core mandate is to transition state care protocols from reactive 'bleed rescue' to proactive, modern 'prophylaxis' care.

Key Clinical Insights & Emerging Evidence
Diagnostic Protocols & Screening Bottlenecks
The panel identified severe diagnostic delays, with patients frequently diagnosed late in life. Recommendations include establishing a standardized statewide diagnostic algorithm, instituting reflex inhibitor testing, expanding basic screening (CBC, PT/aPTT) at district hospitals, and utilizing digital triage tools (phone/WhatsApp) for rapid sample transport and case management.

Multidisciplinary Care & Paramedic Infrastructure
Musculoskeletal preservation requires dedicated physiotherapy support. Medical colleges and HTCs must integrate trained physiotherapists and dedicated paramedic staff. The acknowledgement that NHM will streamline HTC staffing recruitment was welcomed as a vital step forward.

Transitioning from Reactive Bleed Rescue to Prophylaxis
Clinicians emphasized that relying solely on factor replacement after a bleed occurs leads to progressive joint damage, permanent disability, and high & long-term healthcare expenditure. Regular replacement therapy (prophylaxis) must become the baseline standard of care to ensure joint preservation, functional independence and productive human beings.

Real-World Evidence (RWE) on Non-Factor Therapies (Emicizumab)
Deliberations reviewed extensive Indian and global RWE on advanced non-factor therapies (e.g., Emicizumab). Clinical trials and real-world implementation demonstrated near-zero Annualized Bleed Rates (ABR), superior patient compliance via subcutaneous administration, and significant reductions in emergency hospitalizations and costly joint replacement surgeries. Non-factor prophylaxis provides unmatched stability, especially during factor supply-chain disruptions.